ライフサイエンスコーパス: survival

1 unit, length of oxygen support, and overall survival.

2 MRI in predicting kidney graft and patient's survival.

3 response, but also for tumor cell growth and survival.

4 onditioning regimen intensity for relapse or survival.

5 ve oxygen species (ROS) are crucial for cell survival.

6 lopment of acute kidney injury and decreased survival.

7 apy Oncology Group and WHO scales) and 36-mo survival.

8 mbination therapies in prolonging transplant survival.

9 ttern, metastasis-free survival, and overall survival.

10 D-XI) was associated with improved long-term survival.

11 ned with low-dose rapamycin to prolong graft survival.

12 chanism for prolonged epithelioid tumor cell survival.

13 ional changes that promote cell adaption and survival.

14 despite the lack of requirement for neuronal survival.

15 free survival, overall response, and overall survival.

16 lls, slowed tumor growth, and improved mouse survival.

17 ich is strongly correlated with poor patient survival.

18 hods were used to test prediction of overall survival.

19 R duration remains a critical determinate of survival.

20 blation on retinal function or photoreceptor survival.

21 c residents have lower B-CPR rates and lower survival.

22 ents in quality of life but also in terms of survival.

23 al positive MSSA culture was associated with survival.

24 patients with a STR/biopsy resulted in worse survival.

25 rt GRD fitness by improving reproduction and survival.

26 type, organs involved, treatment given, and survival.

27 lost by these mutations is essential to cell survival.

28 iated with recurrence and lower disease-free survival.

29 igher rates of process-of-care compliance or survival.

30 antibody for RNA clearance and improved cell survival.

31 ongly influence density-dependent growth and survival.

32 d mTOR activity and thereby reduces HCC cell survival.

33 , graft quality correlates directly to graft survival.

34 nd antigen-site density most impacted median survival.

35 TLG (p < 0.001) were associated with overall survival.

36 preservation time of 18 h, with 100% 90-day survival.

37 leading to disease attenuation and prolonged survival.

38 M near tumor cells were associated with poor survival.

39 overall survival and distant metastasis free survival.

40 expression of DNMT1 and DNMT3b, and enhanced survival.

41 The primary outcome was long-term survival.

42 p a model that identifies patients with long survival.

43 ons of nourishing and toxic food sources for survival, a fact that necessitates a mechanism for assoc

44 sed differences in carbon stability and tree survival across treatments, expecting that both carbon s

45 Although beneficial for plant survival, active growth inhibition is often undesirable

46 ficantly associated with poorer disease-free survival (adjHR, 1.83; 95% CI, 1.15 to 2.92; P < .01) an

47 ; 95% CI, 1.15 to 2.92; P < .01) and overall survival (adjHR, 2.04; 95% CI, 1.22 to 3.40; P < .01).

48 At 90 days, amputation-free survival (AFS) and Limb salvage (LS) were noticeably wor

49 een associated with improved renal allograft survival after antibody-mediated rejection (AMR).

50 d by PARP inhibitors, thereby promoting cell survival after drug treatment.

51 Long-term survival after minimally invasive esophagectomy was equi

52 However, survival after mMUD remained poor, possibly related to t

53 based on these findings could improve graft survival after SL transplantation, which would encourage

54 However, in those with MELD score >=12, survival after TAVR, SAVR, and medical therapy was simil

55 The relationship between operator volume and survival after unprotected left main stem percutaneous c

56 not associated with worse post-explantation survival (all p > 0.05).

57 suggesting the possibility of a role in cell survival, although a high level of overexpression could

58 We compared survival among persons with and without TB at enrollment

59 ion comparison showed similar improvement in survival among the older population.

60 Adjusted MSPHM survival analyses also found no significant difference i

61 n-free survival analysis and interim overall survival analysis (May 31, 2019), median progression-fre

62 At the time of final progression-free survival analysis and interim overall survival analysis

63 Survival analysis demonstrated treatment success in 70%,

64 Besides, survival analysis demonstrates that the top-ranked miRNA

65 Kaplan-Meier survival analysis revealed that high G9a expression is a

66 Commonly used survival analysis techniques, such as the Kaplan-Meier m

67 We used survival analysis to estimate the relationship between h

68 recautions in a multivariable, discrete time survival analysis, controlling for patient demographics,

69 On univariate survival analysis, TNM stage (p < 0.01), mGPS (p < 0.05)

70 nd prolongation of gestation in a multilevel survival analysis.

71 nd persistently compromised [4-year relative survival and 95% confidence interval: 0.87 (0.85-0.89),

72 r, many NF-kappaB-mediated pathways for cell survival and apoptosis signaling in cancer remain to be

73 el of lung adenocarcinoma improves long-term survival and cisplatin response beyond those of the synt

74 that HUNK expression correlates with overall survival and distant metastasis free survival.

75 Secondary endpoints were survival and inflation-adjusted hospital readmission cha

76 immune evasion strategy used by KSHV for its survival and maintenance in the host.

77 c liver injury in vivo via regulation of HSC survival and migration and affect the immune microenviro

78 exert context-dependent effects on offspring survival and physiology by manipulating both egg TH leve

79 levels to identify mechanisms of tumor cell survival and proliferation in adherent and nonadherent c

80 The genes required for survival and proliferation in blood have not been identi

81 15 (IL-15) is an essential cytokine for the survival and proliferation of natural killer (NK) cells.

82 data suggests that CSF-1 is involved in the survival and proliferation of trophoblast cells in EP.

83 nce of runx1 results in increased myocardial survival and proliferation, and overall heart regenerati

84 ue to its association with poor disease-free survival and promotion of aggressive phenotypes in vitro

85 d how these physiological measures relate to survival and reproductive success across all sampled ind

86 Simultaneously, negative responses of winter survival and reproductive-status change to declining env

87 Secondary end points included overall survival and safety.

88 l, event-free survival, and progression-free survival and safety.

89 effects of radiotherapy timing on event-free survival and subgroup interactions were combined using f

90 hat MEGF11 plays an important role in tumour survival and that overexpression of MEGF11 induces both

91 cancer patients into subtypes with distinct survival and therapy response profiles.

92 transcription factors critical for chordoma survival and upregulated pathways dominated by ATF4-driv

93 mal surface inside macrophage is crucial for survival and virulence of M. tuberculosis ESAT-6, a 6-kD

94 f flowering in different climates to balance survival and, through a post-vernalization effect, repro

95 wild birds and humans, we measured both the "survival" and direct detectability of iridescent and non

96 mRNA and protein levels, RGC development and survival, and chromatin landscape effects, we show that

97 (Child Health-Related Quality of Life, Pain, Survival, and Communication).

98 d within this report include safety, overall survival, and duration of response, in keeping with reco

99 Four-year event-free survival, relapse-free survival, and overall survival rates were 67.7% (95% CI,

100 tions on metastatic pattern, metastasis-free survival, and overall survival.

101 utcomes and complications, graft and patient survival, and predictors of graft and patient survival w

102 endpoints were overall survival, event-free survival, and progression-free survival and safety.

103 rs is associated with high tumor grade, poor survival, and resistance to chemotherapy.

104 -derived whole-body tumor volume for overall survival are poorly elucidated to date.

105 The primary endpoint was progression-free survival assessed by intention to treat.

106 Patient survival at 1, 5, 10, and 15 years was 97.4%, 93.0%, 89.

107 Patient and graft survival at 3 years posttransplantation were 74% (95% CI

108 gimens have been used with poor disease-free survival at long-term follow-up.

109 is of investigator-assessed progression-free survival at the overall survival database lock, median p

110 y factor limiting urban offspring growth and survival, at least in this well-studied species.

111 but wider resection margins do not confer a survival benefit [57 months (95% confidence interval 38.

112 derive a substantial long-term relapse-free survival benefit from targeted therapy (HR [versus place

113 To confirm the stability of the relapse-free survival benefit, longer-term data were needed.

114 n together with the lack of progression-free survival benefit, these findings do not support routine

115 ith FAV are critical factors for obtaining a survival benefit.

116 ained through trade-offs where migrants gain survival benefits by avoiding unfavourable conditions, w

117 sing focus is being placed on the additional survival benefits that could potentially be achieved wit

118 48-53), but we observed variations in 3-year survival between different races in Namibia (from 90% in

119 as to investigate the CVD events (CVDEs) and survival between the patients with FMF-related AA amyloi

120 n behaviour explain important differences in survival but not in the direction predicted by theory.

121 , IGF-1 and HGF support beta cell growth and survival, but in people with type 2 diabetes the destruc

122 ing significantly prolonged progression-free survival compared with a fixed-duration treatment of rit

123 mplexity increased over time, post-operative survival continued to improve.

124 and durable responses in patients with mUC; survival data are encouraging.

125 nation of RNA-seq, Capture Hi-C, and patient survival data suggests that CALCOCO1 and ZC3H10 are targ

126 Survival data were correlated with histopathologic findi

127 sed progression-free survival at the overall survival database lock, median progression-free survival

128 eviously unknown mortalin substrate and cell survival/death effector.

129 centrally integrated into the cell death or survival decisions in plant immunity by modulating multi

130 The 5-year disease-free survival (DFS) rates for patients with T-ALL randomly as

131 d distant recurrence (LR), (iv) disease free survival (DFS), (v) overall survival (OS).

132 nd activity regulation is essential for cell survival, differentiation, and migration.

133 s can favorably or negatively influence host survival during infection.

134 s cellular homeostasis and promotes cellular survival during times of stress.

135 y system-plays an essential role in animals' survival (e.g., detect deviant sounds that signal danger

136 Collectively, the 5-year overall survival estimate of the 16 062 patients in the study co

137 Key secondary endpoints were overall survival, event-free survival, and progression-free surv

138 When compared with expected population survival, excess mortality risks of pure AR, AR + OMR, a

139 idated the crucial role of active STAT5 as a survival factor for functionally differentiated epitheli

140 coagulation, and harbors diverse growth and survival factors.

141 t DNA synthesis at stalled forks and promote survival following replication stress, uncovering an une

142 ble to obtain updated results for event-free survival for 2153 patients recruited between November, 2

143 so found no significant difference in 28-day survival for cases treated with IVF (27.3%) compared to

144 The corresponding 5-year survival for ER and esophagectomy were 53% versus 61% (P

145 cinoma-specific signatures are predictive of survival for human breast cancer patients.

146 for living donors include patient survival, survival free of operative intervention, and data on com

147 We report on biochemical progression-free survival, freedom from non-protocol hormone therapy, saf

148 sticizer and either 60 or 50% PLGA prolonged survival from 27 to 70 days in a GBM xenograft mouse res

149 orhood is associated with B-CPR delivery and survival from out-of-hospital cardiac arrest.

150 Overall survival from TRB was not improved as a result of screen

151 ased in others, indicating a conditional pro-survival function of caspase-8 in cancer.

152 Although gains in newborn survival have been achieved in many low-income and middl

153 Results from the final analysis of overall survival have not yet been reported.

154 2.07 to 3.22; P = 0.67), and long-term graft survival (hazard ratio, 1.07; 95% CI, 0.86-1.33; P = 0.5

155 to 12.10; P < .001), decreased relapse-free survival (HR, 2.94; 95% CI, 1.84 to 4.69; P < .001), and

156 o refine strategies that may perhaps improve survival if mechanical ventilation is pursued in this se

157 erapy; LRT) could be associated with overall survival improvements.

158 %, and 77%, 51%, respectively, comparable to survival in 382 HCC patients without PVTT undergoing upf

159 a granulocyte CN positively correlated with survival in a high-risk patient subset.

160 e nonsignificant trend towards a lower graft survival in CMV high-risk patients treated with belatace

161 ) was found to be crucial for GAS growth and survival in human blood and was validated in another M1T

162 Decisions about when to act are critical for survival in humans as in animals, but how a desire is tr

163 a overexpression significantly increased CSC survival in hypoxia, proangiogenic factors production an

164 at suggests that H(2)S/RSS impacts bacterial survival in infected cells and animals.

165 (2)S is the effector molecule regulating Mtb survival in macrophages.

166 tpone resistance and extend progression-free survival in many cancer indications.

167 hadenectomy leads to better disease-specific survival in patients treated with surgery alone.

168 cellular Matrix Cluster 3), indicated poorer survival in patients with grade III tumors.

169 R0 is the most important predictor of survival in patients with LRRC.

170 Overall survival in patients with relapsed disease remains poor,

171 Survival in primates is facilitated by commensal gut mic

172 ysis (May 31, 2019), median progression-free survival in the intention-to-treat population was 8.2 mo

173 One-year survival in the VA-ECMO cohort was 71%.

174 cks systemic coagulation and improves animal survival in three models of sepsis (cecal ligation and p

175 that is required for growth stimulation and survival in vivo Consequently, B. fragilis acquires esse

176 dial damage, shock, lung injury and improved survival independent of pancreatic injury.

177 nal pigment epithelial cells(ARPE-19), their survival, intracellular localization, and the pathologic

178 aningful impact on cardiovascular health and survival is unknown.

179 s curve revealed that PGSs predicted patient survival more accurately than previously identified canc

180 Because B vitamins are essential for survival, null mutations often have embryo lethal phenot

181 rk activity, likely resulting from defective survival of a subset of limb-innervating motor neurons a

182 development of functional antibodies follows survival of acute EVD.

183 relation between CD82 expression and overall survival of AML patients.

184 mediates enhanced autophagy, leading to the survival of autoreactive lymphocytes and increased autoa

185 wall biogenesis, a process essential to the survival of bacteria.

186 ps of Gelbard and Saxena also show decreased survival of C9-BAC versus NT mice and neuropathological

187 Relative survival of electively treated AAA patients was stable a

188 tions, after MIE negatively affect long-term survival of esophageal cancer patients.

189 cardial infarction (MI) is essential for the survival of existing and regenerated cardiac tissue.

190 l ABCB5 blockade inhibited proliferation and survival of GBM cells and sensitized them to temozolomid

191 CD8(+) T cells, by enhancing the quality and survival of immune responses.

192 fb conditional deletion (cDKO) decreases the survival of MGE-derived cortical interneurons (CINs) and

193 nce of lung metastasis and increased overall survival of mice when injected into mammary fat pad of s

194 ment in proteome flux may play a role in the survival of N2a cells upon prion infection.

195 Methods: Safety and survival of patients with metastatic castration-resistan

196 clinical profile, myocardial remodeling, and survival of patients with PPCM in Nigeria.

197 ides and tetracyclines substantially improve survival of plague, and fluoroquinolones may be equally

198 may play a beneficial role in preserving the survival of PV(+) neurons, and that inhibition of the im

199 onditions change and the long-term continued survival of right whales remains uncertain.

200 a murine model of osteomyelitis, we examined survival of S. aureus mutants deficient in central metab

201 bolic mechanism that ensures homeostasis and survival of the cell in the face of stressors as differe

202 in complexes implicated in intraerythrocytic survival of the parasite.

203 hogen that causes white-nose syndrome (WNS), survival of the species may ultimately depend upon its c

204 l repertoire, suggesting antigen-independent survival of this subset.

205 Here, using the melanoma lineage survival oncogene MITF as a model, we show that low-affi

206 d functions to influence their intracellular survival or evade host immunity.

207 oxygen has a positive or negative effect on survival or progression to long-term oxygen therapy in p

208 postoperative deaths, 1- and 5-year overall survival (OS) and recurrence-free survival (RFS) were 82

209 tive groups to improve prognosis for overall survival (OS) and relapse free survival (RFS) outcomes.

210 Overall survival (OS) differed significantly among ELN risk grou

211 both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ip

212 linicopathologic characteristics and overall survival (OS) of PDA patients.

213 Median overall survival (OS) was 18 months (95% CI, 8-27); 5-year OS wa

214 rences in progression-free (PFS) and overall survival (OS) were evaluated using log-rank tests and Co

215 Long-term outcomes, including overall survival (OS), recurrence-free survival (RFS), disease-s

216 progression-free survival (PFS) and overall survival (OS).

217 iv) disease free survival (DFS), (v) overall survival (OS).

218 i2 p = 0.001) and 15 fewer months of overall survival (OS; 95% CI -1 to 31, 92-120 versus 113-129 mon

219 found adverse events and large variations in survival outcome.

220 an tumor Tregs and was associated with worse survival outcomes in patients with multiple tumor types.

221 reditary genetics can impact progression and survival outcomes of a future malignancy and warrant pro

222 NOM) on long-term healthcare utilization and survival outcomes.

223 The primary endpoints were event-free survival, overall response, and overall survival.

224 d associated with divergent progression-free survival patterns.

225 Objective response rate and progression-free survival per investigator assessment were recorded.

226 sing left-truncation with increasing minimum survival period.

227 ted with 17 fewer months of progression-free survival (PFS) (95% confidence interval [CI] 5-29, 49-69

228 pplied to predict patients' progression-free survival (PFS) and overall survival (OS).

229 Progression-free survival (PFS), OS, and adverse events were also assesse

230 raphic characteristics with progression-free survival (PFS; by RECIST) were evaluated by Cox regressi

231 n prenatal mice and it is critical for their survival postnatally.

232 comparable results with regard to long-term survival, postoperative morbidity, mortality and patholo

233 Different survival probabilities for prostate disorder and prostat

234 arkers, considering their ability to predict survival probability in FTLD.

235 ts, expecting that both carbon stability and survival probability would increase with increasing trea

236 A hospital's risk-standardized survival rate (RSSR) for in-hospital cardiac arrest has

237 nhanced autophagy and improved intracellular survival rates compared to those of wild-type bacteria i

238 ained challenging to treat in children, with survival rates lagging well behind those observed at ini

239 nsistently disappointing with 5-year overall survival rates of ~10%.

240 , 95% CI 0.58-0.82); 8-year landmark overall survival rates were 37% (95% CI 31-42) in the pertuzumab

241 survival, relapse-free survival, and overall survival rates were 67.7% (95% CI, 55.9% to 79.4%), 72.9

242 ), delayed graft function, patient and graft survival rates, and renal function.

243 Four-year event-free survival, relapse-free survival, and overall survival ra

244 k-in mice exhibited IL-1-dependent increased survival relative to wild-type knock-in mice.

245 Risk: 2.129, p < 0.0001) and recurrence-free survival (Relative Risk: 1.299, p < 0.0001) in patients

246 t independent prognostic factors for overall survival (Relative Risk: 2.129, p < 0.0001) and recurren

247 vival database lock, median progression-free survival remained significantly improved with ramuciruma

248 ed significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose i

249 s for overall survival (OS) and relapse free survival (RFS) outcomes.

250 ar overall survival (OS) and recurrence-free survival (RFS) were 82%, 57%, and 77%, 51%, respectively

251 uding overall survival (OS), recurrence-free survival (RFS), disease-specific mortality (DSM), and ti

252 Erythropoietin (EPO) provides the major survival signal to maturing erythroid precursors (EPs) a

253 -1 monomer, ensuring long-term photoreceptor survival.SIGNIFICANCE STATEMENT Visual arrestin-1 forms

254 Understanding bacterial defense and survival strategies against one of the most powerful neu

255 hat entombment in halite may be an effective survival strategy for near complete communities of haloa

256 suggests that maternal effects on early life survival such as maternal age may act through their infl

257 The dependency of lymphomas on MNT for survival suggests that drugs inhibiting MNT could signif

258 me metrics for living donors include patient survival, survival free of operative intervention, and d

259 on therapy resulted in longer median overall survival than placebo plus androgen-deprivation therapy

260 ates and longer progression-free and overall survival than those with NMRs <5.75.

261 o localized bacterial infections and reduced survival that is, at least in part, neutrophil mediated.

262 To ensure their survival, these bacteria rely on chemosensory pathways t

263 ave persisted twice as long as the predicted survival time for selectively neutral nuclear alleles.

264 We evaluated the factors associated with survival time in a large cohort of HIV/HTLV-1-coinfected

265 NAs are significantly related to the overall survival time in the breast and liver cancers group.

266 vasion in mice and significantly reduces the survival time of the mice with tumor.

267 .1; P < .0001), and shorter disease-specific survival times (hazard ratio, 23.1; P < .0001).

268 w levels of PD-1 were associated with longer survival times of patients.

269 nts, the median progression-free and overall survival times were not yet reached, with only 1 patient

270 s, but surprisingly, loss of PQM-1 increases survival under hypoxic conditions.

271 ion between cell states promotes cancer cell survival under stress and fosters non-genetic heterogene

272 coneogenesis is essential for the organismal survival upon prolonged fasting and maintaining systemic

273 the EZH2(WT) cohort; median progression-free survival was 13.8 months (10.7-22.0) and 11.1 months (3.

274 In the high PD-L1 population, median overall survival was 14.4 months (95% CI 10.4-17.3) in the durva

275 Median progression-free survival was 14.5 months (95% CI 12.5-17.7) in the velip

276 3-year overall survival was 50% (95% CI 48-53), but we observed variati

277 Median overall survival was 57.1 months (95% CI 50-72) in the pertuzuma

278 w-up of 44 months (26-53), 4-year event-free survival was 59% (95% CI 48-73); 69% (54-87) in adolesce

279 wer needed for significance), 4-year overall survival was 77.9% (95% CI 73.7-81.5) with nivolumab and

280 Overall survival was 83.3% (95% confidence interval [CI], 76.2-8

281 Post-operative survival was assessed using time-dependent Cox proportio

282 utcome of continued climate change on summer survival was generally positive.

283 However, without competitors, L. picturatus survival was greater at high-elevation than low-elevatio

284 Winter survival was largely driven by conditions during the pre

285 Survival was modeled by using Cox proportional hazards r

286 al profile of mitochondrial salvage and cell survival was observed in the EVLP lung tissue compared w

287 Overall survival was significantly different between patients wi

288 The negative effect on apparent survival was stronger with increasing relative load of t

289 low-up of 70 months, rates of 5-year overall survival were 54% in the laparoscopic group and 55% in t

290 urvival, and predictors of graft and patient survival were assessed.

291 Recurrence and survival were indexed at 6 months after enrollment using

292 oss racial and ethnic groups, differences in survival were markedly attenuated and hazard ratios appr

293 equent reports, progression-free and overall survival were significantly improved in the pertuzumab g

294 trol of feeding behavior and help organism's survival when they support physiological needs.

295 e a multigenerational enhancement of progeny survival when three consecutive generations of animals a

296 TP53 are associated with poorer CRC-specific survival, which is most pronounced in cases carrying TP5

297 rent 36 months to the duration of transplant survival will result in better patient outcomes and cost

298 Patient survival with end-stage renal disease is longer after ki

299 DPSC and DPSC-CM significantly enhanced TGNC survival with extensive neurite outgrowth and branching

300 Host survival would facilitate virus spread, which would also